135 related articles for article (PubMed ID: 35099298)
1. Glycemic Effects and Predictors of Increased Time-in-Range After Initiating MiniMed 670G: A 12-Month Observational Study.
Jacobsen SS; Hommel E; Ranjan AG; Nørgaard K
Diabetes Technol Ther; 2022 Aug; 24(8):592-597. PubMed ID: 35099298
[TBL] [Abstract][Full Text] [Related]
2. Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch.
Stone MP; Agrawal P; Chen X; Liu M; Shin J; Cordero TL; Kaufman FR
Diabetes Technol Ther; 2018 Oct; 20(10):689-692. PubMed ID: 30160523
[TBL] [Abstract][Full Text] [Related]
3. Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review.
Mameli C; Smylie GM; Galati A; Rapone B; Cardona-Hernandez R; Zuccotti G; Delvecchio M
Eur J Pediatr; 2023 May; 182(5):1949-1963. PubMed ID: 36809498
[TBL] [Abstract][Full Text] [Related]
4. Safety and Glycemic Outcomes During the MiniMed
Pihoker C; Shulman DI; Forlenza GP; Kaiserman KB; Sherr JL; Thrasher JR; Buckingham BA; Kipnes MS; Bode BW; Carlson AL; Lee SW; Latif K; Liljenquist DR; Slover RH; Dai Z; Niu F; Shin J; Jonkers RAM; Roy A; Grosman B; Vella M; Cordero TL; McVean J; Rhinehart AS; Vigersky RA;
Diabetes Technol Ther; 2023 Nov; 25(11):755-764. PubMed ID: 37782145
[No Abstract] [Full Text] [Related]
5. Increased proportion of time in hybrid closed-loop "Auto Mode" is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump.
Duffus SH; Ta'ani ZA; Slaughter JC; Niswender KD; Gregory JM
Diabetes Obes Metab; 2020 Apr; 22(4):688-693. PubMed ID: 31709736
[TBL] [Abstract][Full Text] [Related]
6. Fast-Acting Insulin Aspart Use with the MiniMed
Hsu L; Buckingham B; Basina M; Ekhlaspour L; von Eyben R; Wang J; Lal RA
Diabetes Technol Ther; 2021 Jan; 23(1):1-7. PubMed ID: 32520594
[No Abstract] [Full Text] [Related]
7. Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study.
Lepore G; Scaranna C; Corsi A; Dodesini AR; Trevisan R
Diabetes Technol Ther; 2020 Apr; 22(4):321-325. PubMed ID: 31617752
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
[TBL] [Abstract][Full Text] [Related]
9. Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial.
Garg SK; Grunberger G; Weinstock R; Lawson ML; Hirsch IB; DiMeglio LA; Pop-Busui R; Philis-Tsimikas A; Kipnes M; Liljenquist DR; Brazg RL; Kudva YC; Buckingham BA; McGill JB; Carlson AL; Criego AB; Christiansen MP; Kaiserman KB; Griffin KJ; Forlenza GP; Bode BW; Slover RH; Keiter A; Ling C; Marinos B; Cordero TL; Shin J; Lee SW; Rhinehart AS; Vigersky RA;
Diabetes Technol Ther; 2023 Jan; 25(1):1-12. PubMed ID: 36472543
[No Abstract] [Full Text] [Related]
10. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes.
Petrovski G; Al Khalaf F; Campbell J; Umer F; Almajaly D; Hamdan M; Hussain K
Acta Diabetol; 2021 Feb; 58(2):207-213. PubMed ID: 33044604
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System.
Messer LH; Forlenza GP; Sherr JL; Wadwa RP; Buckingham BA; Weinzimer SA; Maahs DM; Slover RH
Diabetes Care; 2018 Apr; 41(4):789-796. PubMed ID: 29444895
[TBL] [Abstract][Full Text] [Related]
12. Six-Month Effectiveness of Advanced
Tornese G; Buzzurro F; Carletti C; Faleschini E; Barbi E
Front Endocrinol (Lausanne); 2021; 12():766314. PubMed ID: 34858339
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Real-Life Usage of MiniMed 670G Automode in Children with Type 1 Diabetes Less than 7 Years Old.
Salehi P; Roberts AJ; Kim GJ
Diabetes Technol Ther; 2019 Aug; 21(8):448-451. PubMed ID: 31166801
[TBL] [Abstract][Full Text] [Related]
14. Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States.
Arunachalum S; Velado K; Vigersky RA; Cordero TL
J Diabetes Sci Technol; 2023 Jul; 17(4):951-958. PubMed ID: 35414272
[TBL] [Abstract][Full Text] [Related]
15. Fast-acting insulin aspart (Fiasp®) improves glycemic outcomes when used with MiniMed
Grosman B; Wu D; Parikh N; Roy A; Voskanyan G; Kurtz N; Sturis J; Cohen O; Ekelund M; Vigersky R
Comput Methods Programs Biomed; 2021 Jun; 205():106087. PubMed ID: 33873075
[TBL] [Abstract][Full Text] [Related]
16. Predicting Success with a First-Generation Hybrid Closed-Loop Artificial Pancreas System Among Children, Adolescents, and Young Adults with Type 1 Diabetes: A Model Development and Validation Study.
Forlenza GP; Vigers T; Berget C; Messer LH; Lal RA; Basina M; Maahs DM; Hood K; Buckingham B; Wilson DM; Wadwa RP; Driscoll KA; Pyle L
Diabetes Technol Ther; 2022 Mar; 24(3):157-166. PubMed ID: 34780306
[No Abstract] [Full Text] [Related]
17. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.
Bergenstal RM; Nimri R; Beck RW; Criego A; Laffel L; Schatz D; Battelino T; Danne T; Weinzimer SA; Sibayan J; Johnson ML; Bailey RJ; Calhoun P; Carlson A; Isganaitis E; Bello R; Albanese-O'Neill A; Dovc K; Biester T; Weyman K; Hood K; Phillip M;
Lancet; 2021 Jan; 397(10270):208-219. PubMed ID: 33453783
[TBL] [Abstract][Full Text] [Related]
18. 10-Day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes.
Petrovski G; Al Khalaf F; Campbell J; Fisher H; Umer F; Hussain K
Acta Diabetol; 2020 Jun; 57(6):681-687. PubMed ID: 31953687
[TBL] [Abstract][Full Text] [Related]
19. Real-World Patient Experience of Long-Term Hybrid Closed-Loop Insulin Pump Use.
Wang LR; Malcolm J; Arnaout A; Humphrey-Murto S; LaDonna KA
Can J Diabetes; 2021 Dec; 45(8):750-756.e3. PubMed ID: 33958309
[TBL] [Abstract][Full Text] [Related]
20. Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Over Predictive Low-Glucose Suspend Technology.
Beato-Víbora PI; Gallego-Gamero F; Lázaro-Martín L; Romero-Pérez MDM; Arroyo-Díez FJ
Diabetes Technol Ther; 2020 Dec; 22(12):912-919. PubMed ID: 31855446
[No Abstract] [Full Text] [Related]
[Next] [New Search]